EUVIMEDEUVIMED entdecken
Crossref

Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure

Yasushi Nakai, Nobumichi Tanaka, Isao Asakawa, Kenta Onishi, Makito Miyake, Kaori Yamaki, Kiyohide Fujimoto

Brachytherapy · 2024-11 · 23 (6) · 727-736

DOI: 10.1016/j.brachy.2024.09.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2024-11. Verfasst von Yasushi Nakai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Brachytherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to assess if prostate-specific antigen (PSA) threshold and PSA bounce are associated with oncological control after low-dose-rate brachytherapy (LDR-BT) alone or with external beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT), considering serum testosterone levels. METHODS: This study enrolled 944 prostate cancer patients treated at a single institution with LDR-BT alone or LDR-BT combined with EBRT, with or without ADT. The Fine-Gray hazard model was used to evaluate factors related to clinical failure, including experience of PSA bounce between baseline and 2, 4, or 7 years after LDR-BT and PSA value (0.1, 0.2, or 0.5 ng/mL) with normal testosterone levels at 2, 4, and 7 years after LDR-BT, respectively. RESULTS: Patients with normal testosterone levels and a PSA of 0.2 or 0.5 ng/mL at 2, 4, and 7 years after LDR-BT had a significantly better clinical failure free rate (CFFR) than those with PSA levels >0.2 or >0.5 ng/mL or low testosterone levels. Multivariate analysis revealed that PSA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsBrachytherapyHumansMaleAgedMiddle AgedRadiotherapy DosageTreatment FailureTestosteroneAged, 80 and overBiomarkers, TumorRetrospective StudiesPrognosis

Stichwörter der Autor:innen

BrachytherapyPSA kineticsProstate cancerProstate-specific antigen

Substanzen

Prostate-Specific AntigenTestosteroneBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan.
  • Department of Urology, Nara Medical University, Nara, Japan; Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan. Electronic address: sendo@naramed-u.ac.jp.
  • Department of Prostate Brachytherapy, Nara Medical University, Nara, Japan; Department of Radiation Oncology, Nara Medical University, Nara, Japan.
  • Department of Urology, Nara Medical University, Nara, Japan.
  • Department of Radiation Oncology, Nara Medical University, Nara, Japan.

Zitieren

APA

Nakai, Y., Tanaka, N., Asakawa, I., Onishi, K., Miyake, M., Yamaki, K., & Fujimoto, K. (2024). Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure. Brachytherapy, 23(6), 727-736. https://doi.org/10.1016/j.brachy.2024.09.003

Vancouver

Nakai Y, Tanaka N, Asakawa I, Onishi K, Miyake M, Yamaki K, et al. Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure. Brachytherapy. 2024;23(6):727-736. doi:10.1016/j.brachy.2024.09.003

BibTeX
@article{Nakai2024,
  author = {Nakai, Yasushi and Tanaka, Nobumichi and Asakawa, Isao and Onishi, Kenta and Miyake, Makito and Yamaki, Kaori and Fujimoto, Kiyohide},
  title = {Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure},
  journal = {Brachytherapy},
  year = {2024},
  volume = {23},
  number = {6},
  pages = {727--736},
  doi = {10.1016/j.brachy.2024.09.003}
}
Kostenlos starten →